share_log

Avenue Therapeutics | 8-K: Current report

SEC announcement ·  May 23 20:35
Summary by Futu AI
On May 21, 2024, Avenue Therapeutics, Inc. announced that it had received formal notice from The Nasdaq Stock Market LLC confirming the company's compliance with all necessary criteria for continued listing on The Nasdaq Capital Market. This includes meeting the minimum stockholders' equity requirement. The compliance notice effectively closes a previously disclosed listing issue. However, Avenue Therapeutics will be monitored by a Nasdaq Panel for one year until May 21, 2025. During this period, if the company fails to meet the Equity Rule, it will not be allowed to submit a compliance plan but will instead need to request a hearing before the Nasdaq Hearings Panel to address the deficiency.
On May 21, 2024, Avenue Therapeutics, Inc. announced that it had received formal notice from The Nasdaq Stock Market LLC confirming the company's compliance with all necessary criteria for continued listing on The Nasdaq Capital Market. This includes meeting the minimum stockholders' equity requirement. The compliance notice effectively closes a previously disclosed listing issue. However, Avenue Therapeutics will be monitored by a Nasdaq Panel for one year until May 21, 2025. During this period, if the company fails to meet the Equity Rule, it will not be allowed to submit a compliance plan but will instead need to request a hearing before the Nasdaq Hearings Panel to address the deficiency.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.